Pentetic acid

Pentetic acid Overview

Pentetic acid (chemically designated as diethylenetriaminepentaacetic acid, or DTPA; chemical formula C14H23N3O10) is a synthetic polyamino carboxylic acid. Chemically, it belongs to the class of organic compounds known as pentacarboxylic acids and derivatives within the carboxylic acids and derivatives sub-class of organic acids. Structurally, it consists of a diethylenetriamine core backbone conjugated to five carboxymethyl groups, providing eight coordinate bond-forming donor sites (three nitrogen atoms and five carboxyl oxygen atoms) capable of forming highly stable, multidentate coordination complexes with heavy metal cations and transuranic radionuclide ions.

In nuclear medicine, radiation emergency response, and nephrology, Pentetic acid functions as a heavy metal chelating agent, radionuclide decorporation antidote, and diagnostic radiopharmaceutical ligand. Formulated as calcium trisodium (Ca-DTPA) and zinc trisodium (Zn-DTPA) intravenous injection concentrates, as well as lyophilized kits for Technetium Tc-99m preparation (marketed under trade names such as Pentetate Calcium Trisodium, Pentetate Zinc Trisodium, and Draximage DTPA), it is indicated for the treatment of internal contamination with transuranic elements (plutonium, americium, or curium) to increase their clearance and renal elimination rates. When radiolabeled with technetium-99m (Tc-99m DTPA), it is used in diagnostic nuclear medicine to evaluate glomerular filtration rate (GFR), renal perfusion, obstructive uropathy, radionuclide cisternography, and pulmonary epithelial permeability.

What Is Pentetic acid and How Does It Work?

Pentetic acid acts primarily through multidentate chelation of multivalent metal and transuranic radionuclide cations, forming stable, water-soluble coordination complexes cleared rapidly by renal glomerular filtration.

Its primary chemical, physiological, and pharmacological mechanisms include:

• Transuranic Radionuclide Exchange & Chelation: In its Ca-DTPA and Zn-DTPA salt formulations, DTPA exchanges its weakly bound calcium or zinc cations for transuranic metal ions (such as Pu-239, Am-241, or Cm-244), which possess significantly higher thermodynamic binding affinity. The resulting octa-coordinate radionuclide-DTPA complex sequesters the toxic radioisotope.
• Rapid Renal Excretion of Radiocontaminants: The highly hydrophilic radionuclide-DTPA complex circulates in blood plasma without binding to plasma proteins or depositing in organ tissues, and is filtered rapidly and unchanged by renal glomeruli into urine, drastically shortening the biological half-life of internal radiation sources.
• Glomerular Filtration Rate (GFR) Marker (Tc-99m DTPA): When radiolabeled with Technetium-99m, the Tc-99m DTPA complex functions as a pure renal filtration agent. It is cleared exclusively by glomerular filtration without tubular secretion or reabsorption, allowing accurate quantitative Gamma camera measurement of relative renal function, effective renal plasma flow, and total GFR.
• Pulmonary Aerosol Diffusion: When administered via nebulized inhalation, Tc-99m DTPA aerosol crosses the alveolar-capillary membrane by passive diffusion, serving as a diagnostic index of pulmonary epithelial permeability in acute respiratory distress syndromes or interstitial lung disease.

Is Pentetic acid FDA Approved?

Pentetic acid formulations, specifically Pentetate Calcium Trisodium and Pentetate Zinc Trisodium injections, were approved by the US FDA in April 2004 for the treatment of internal radiation contamination. Its current approval status is FDA Approved (April 2004).

What Is Pentetic acid Used For?

• Treatment of individuals with known or suspected internal contamination with transuranic elements (plutonium, americium, or curium) to increase their elimination rates.
• Diagnostic radiologic evaluation of glomerular filtration rate (GFR), renal perfusion, and renal structure using Tc-99m DTPA.
• Diagnostic radionuclide cisternography (via intrathecal indium In-111 DTPA) to evaluate cerebrospinal fluid (CSF) flow dynamics and detect leaks.
• Diagnostic pulmonary ventilation imaging and alveolar permeability measurement via aerosolized Tc-99m DTPA.

Before Taking Pentetic acid: Contraindications & Precautions

Do not administer Ca-DTPA to patients with severe leukopenia, severe thrombocytopenia, or uncorrected hypocalcemia. Ca-DTPA and Zn-DTPA must not be administered simultaneously; when continuous decorporation is required, Ca-DTPA is given as the initial single dose, followed by Zn-DTPA for long-term maintenance to prevent life-threatening depletion of essential trace minerals. Nebulized inhalation should be used with extreme caution in patients with severe asthma or chronic obstructive pulmonary disease (COPD) due to the risk of triggering severe bronchospasm.

Who Should Not Take Pentetic acid?

• Individuals with known severe hypersensitivity to Pentetic acid, DTPA salts, or formulation excipients.
• Patients with severe, uncorrected baseline nephrotic syndrome or acute anuric renal failure (decorporation efficacy depends entirely on renal urinary output).

Pentetic acid, Pregnancy & Safety

Ca-DTPA carries a higher risk of teratogenicity and fetal toxicity than Zn-DTPA because Ca-DTPA heavily chelates and depletes maternal endogenous zinc and manganese pools necessary for fetal development. During pregnancy, if transuranic decorporation is urgently required, Zn-DTPA is the preferred initial agent unless internal radiation contamination is exceptionally high, in which case a single initial dose of Ca-DTPA may be given followed immediately by Zn-DTPA. Breastfeeding should be discontinued following internal radiocontamination or radiopharmaceutical administration.

Tell Your Doctor Before Taking Pentetic acid

Inform your physician or radiation medical officer if you have a history of chronic kidney disease, severe asthma, impaired lung function, mineral deficiencies, or heart disease.

Pentetic acid Dosage & Administration

Formulated as sterile solution concentrates (200 mg/mL Ca-DTPA or Zn-DTPA in 5 mL single-dose ampoules) for intravenous injection or nebulized inhalation, and as lyophilized kits for Technetium Tc-99m radiolabeling.

Standard Pentetic acid Dosing

• Internal Transuranic Contamination Decorporation (Adults & Adolescents): Administered as 1.0 gram IV (or 1.0 gram nebulized inhalation) as a single dose. If treatment is initiated within 24 hours of exposure, give Ca-DTPA 1.0 g IV as the first dose. If treatment continues beyond 24 hours, switch to Zn-DTPA 1.0 g IV once daily until decorporation is complete.
• Pediatric Decorporation Dosing (Under 12 Years): Administered as 14 mg/kg IV (maximum 1.0 gram per dose).

How Pentetic acid Is Administered

• Administered intravenously by slow bolus injection over 3 to 4 minutes, or as an intravenous infusion diluted in 100 mL to 250 mL of 5% dextrose or 0.9% sodium chloride over 30 to 60 minutes.
• Alternatively administered via nebulizer (diluted 1:1 with sterile water or saline) for localized inhalation following inhalation-pathway radiocontamination.

Pentetic acid Clinical Efficacy & Safety Profile

In radiation emergency medical management, prompt administration of Ca-DTPA within hours of transuranic exposure increases the urinary excretion of plutonium and americium by 10 to 100 times compared to untreated individuals. Transitioning to Zn-DTPA for long-term maintenance maintains decorporation efficacy while protecting against depletion of endogenous trace metals (zinc, manganese). In diagnostic nuclear nephrology, Tc-99m DTPA clearance correlates well with inulin clearance for measurement of GFR.

Pentetic acid Side Effects & Safety Profile

Common adverse effects include headache, lightheadedness, nausea, metallic taste, injection site reactions, fever, and transient chest tightness. Serious adverse risks include severe essential trace element depletion (zinc and manganese), severe hypocalcemia, acute tubular necrosis, severe bronchospasm during inhalation, and allergic anaphylaxis. Holds no FDA Black Box Warning.

Common Pentetic acid Side Effects

• Systemic & Local: Metallic taste, transient nausea, vomiting, diarrhea, headache, lightheadedness, injection site pain, chills, and fever.
• Respiratory (Inhalation Route): Mild cough, transient wheezing, and pharyngeal irritation.

Serious Pentetic acid Adverse Events

• Essential Trace Element Depletion: Prolonged or repeated Ca-DTPA administration causes severe depletion of endogenous zinc, manganese, and magnesium, leading to bone marrow depression, dermatitis, and gastrointestinal lesions.
• Renal Tubular Toxicity: High-dose DTPA can induce acute renal tubular vacuolization and transient acute renal failure.
• Severe Bronchospasm: Inhalation of nebulized DTPA solutions can trigger acute airway constriction in hyperreactive asthma patients.

Managing Pentetic acid Side Effects

Monitor serum electrolytes, zinc levels, urinalysis, and renal function regularly during decorporation therapy. Treat acute bronchospasm with inhaled short-acting beta-agonists. Switch Ca-DTPA to Zn-DTPA after the initial 24 hours of exposure.

Pentetic acid Drug Interactions & What to Avoid

Co-administration with other heavy metal chelators requires clinical caution.

Pentetic acid Drug-Drug Interactions

• Other Chelating Agents (e.g., Dimercaprol, Edetate Disodium): Concurrent use can cause unpredictable competitive binding and severe synergistic depletion of essential serum minerals.
• Oral Zinc or Mineral Supplements: Concomitant oral zinc supplements taken during Zn-DTPA therapy reduce the chelation clearance of radionuclides by competing for binding sites.

Pentetic acid, Food & Alcohol

Systemic intravenous and nebulized administration is unaffected by food. Maintain adequate fluid intake to encourage high urine output and protect renal tubules during radionuclide excretion.

Pentetic acid: Missed Dose, Overdose & Storage

Dosing during radiologic emergencies is closely managed by medical staff. Overdose causes mineral depletion and renal strain. Store ampoules at controlled room temperature (15°C–25°C).

Missed Dose of Pentetic acid

In a radiation decorporation scenario, if a daily dose of Zn-DTPA is missed, administer it as soon as remembered on the same day, then return to the daily schedule. Do not administer double doses.

Pentetic acid Overdose & Emergency

Overdose of Ca-DTPA causes severe, acute depletion of zinc and manganese, neuromuscular hyperexcitability due to electrolyte shifts, and acute renal tubular damage. Treatment involves immediate cessation of Ca-DTPA, intravenous supplementation of zinc and essential minerals, and supportive renal hydration.

How to Store Pentetic acid

Store solution concentrates and lyophilized kits at controlled room temperature between 15°C and 25°C (59°F to 77°F). Do not freeze. Protect from light. Keep strictly out of reach of children.

Pentetic acid Patient Management & Monitoring

Requires routine urinalysis, renal function testing, and mineral level tracking during radiation decorporation.

Tests Before Starting Pentetic acid

Baseline radio-bioassay (urinary, fecal, and blood radiocontamination levels), complete blood count (CBC), serum electrolytes, serum creatinine, blood urea nitrogen (BUN), baseline serum zinc, and urinalysis.

Monitoring During Pentetic acid Treatment

Daily tracking of 24-hour urinary radiocontamination clearance; weekly CBC and serum mineral levels (zinc, calcium, manganese); continuous renal function monitoring (BUN and serum creatinine).

Pentetic acid Do’s and Don’ts

• Do maintain high oral fluid intake during decorporation treatment to promote renal radionuclide clearance.
• Do collect all urine for 24-hour radiocontamination bioassay testing as directed by radiation safety personnel.
• Do not take oral zinc supplements simultaneously with Zn-DTPA doses.
• Do not continue Ca-DTPA therapy beyond 24 hours if Zn-DTPA is available.

Frequently Asked Questions

References

• DrugBank Database – Pentetic Acid Clinical Profile (DB14007)
• Classyfire Database – Pentacarboxylic Acids and Derivatives Taxonomy Profile
• US FDA Prescribing Information – Pentetate Calcium Trisodium and Pentetate Zinc Trisodium Injections

Legal Disclaimer

The detailed medical and chemical information provided on this specific web page is intended strictly for educational and informational purposes regarding complex pharmacological mechanisms. It absolutely does not constitute professional medical advice, medical diagnosis, or specific treatment recommendations. Always consult a licensed healthcare provider before making any personal decisions regarding complex medical conditions, medication adjustments, or dietary changes.